Teleflex Inc Stock Price, News & Analysis

Teleflex has received FDA 510(k) clearance for expanded indications of its QuikClot Control+™ Hemostatic Device, now approved for all grades of internal and external bleeding. This expansion significantly broadens the device's applications beyond its previous indications for specific surgical procedures and bleeding types.

The clearance was supported by real-world evidence from a study of 603 emergency, trauma, and surgical patients across multiple U.S. sites. The expanded indication is expected to add over $150 million to Teleflex's serviceable addressable market in the United States.

The device can now be used for temporary control of external and internal bleeding ranging from mild to life-threatening cases. Already commercialized in the European Union in 2024, this development allows Teleflex to target additional procedures in trauma, general surgery, gynecologic surgery, and orthopedic surgery, potentially improving clinical and economic outcomes.

Teleflex (NYSE:TFX) has announced multiple clinical studies and educational sessions to be presented at the 2025 American Urological Association Annual Meeting in Las Vegas from April 26-29, 2025.

The presentations will focus on clinical and real-world evidence supporting innovations in benign prostatic hyperplasia (BPH) treatment and rectal spacing for prostate cancer radiation treatment. Key studies include the CLEAR Randomized Controlled Trial comparing UroLift™ PUL versus Rezum WVTT, the IMPACT trial evaluating UroLift™ PUL versus medication, and research on the safety of stabilized hyaluronic acid as a rectal spacer.

The company will host several educational events, including a Semi-Live Barrigel Case Review, an APP educational breakfast on efficient urology practice, and a Prostate Health Symposium at Allegiant Stadium. Daily presentations will also take place at Teleflex booth 1401, featuring discussions on both the Barrigel™ rectal spacer and UroLift™ System.

Teleflex (NYSE:TFX) has scheduled its first quarter 2025 earnings conference call for Thursday, May 1, 2025, at 8:00 a.m. Eastern Time. The company will present its Q1 financial results and provide an operational update during the call.

Participants can access the call through pre-registration or via a live audio webcast on teleflex.com. An audio replay will be available from 11:00 am ET on the same day, accessible through the company website or by phone at 1-800-770-2030 (U.S./Canada) or 1-609-800-9909 (other locations) using conference ID 69028.

Teleflex (NYSE: TFX) has received FDA 510(k) clearance for its new AC3 Range™ Intra-Aortic Balloon Pump (IABP). This innovative medical device is specifically designed for patient transport across various modes, including ambulances and aircraft.

The AC3 Range™ IABP builds upon the patented technology of the AC3 Optimus™ IABP, featuring a simple interface and proprietary algorithms for precise cardiac support. Key transport-focused features include:

• Full-size helium tank
• Dual power options
• Metal-reinforced extendable handle
• Four 360-degree swivel wheels

The device will enter full market release in the United States with shipments beginning in the second quarter of 2025. Teleflex will showcase both the AC3 Optimus™ and AC3 Range™ IABPs at the upcoming ISHLT Annual Meeting in Boston.

Teleflex (NYSE: TFX) announced preliminary results from its Ringer™ PBC IDE study at the CTO Plus Conference, investigating a novel perfusion balloon catheter for managing coronary perforations. The study enrolled 30 participants across four US sites.

The Ringer™ PBC features a unique helical balloon design allowing continuous coronary blood flow during inflation. Key results showed:

• Primary efficacy endpoint achieved in 73.3% of participants (22/30)
• Successful device delivery in 86.7% of cases (26/30)
• Control of extravasation with perfusion in 84.6% of successful deliveries (22/26)

The device has received FDA's Breakthrough Device Designation for coronary perforation management. Twelve participants required covered stent treatment post-procedure, one needed emergency surgery, and three deaths occurred despite controlled extravasation. A premarket application has been submitted to FDA.

Teleflex (NYSE: TFX) presented new findings from the CLEAR study at the 40th Annual European Association of Urology Congress in Madrid. The study, comparing UroLift™ System (PUL) with Rezūm™ Water Vapor Therapy (WVTT) for benign prostatic hyperplasia (BPH) treatment, revealed superior outcomes for UroLift™.

Key findings include:

• Only 1 out of 42 UroLift™ patients failed to achieve catheter independence within 3-7 days post-procedure, compared to 10 out of 37 Rezūm patients
• UroLift™ patients reported less interference with daily activities due to pain and blood in urine
• Better sexual function outcomes were observed in UroLift™ patients, with improved erectile and orgasmic function at one month
• Higher patient satisfaction scores were recorded for UroLift™ at both 14 days and one-month post-procedure

Cagent Vascular has appointed Paul Wilson as Chief Commercial Officer (CCO) to lead the company's commercial strategy. Wilson, who previously held senior leadership positions at Teleflex (TFX) and Abbott, will oversee sales, marketing, clinical programming, and business development initiatives.

The company's proprietary serration balloon technology, including the FDA-cleared Serranator® and Serranator SL-PRO™ PTA Serration Balloon Catheters, uses stainless steel micro-serration technology for vessel dilation in endovascular interventions. The technology delivers 1,000x more point force compared to traditional balloon angioplasty, creating linear, interrupted scoring during slow-and-low balloon inflation to optimize vessel preparation and enhance arterial expansion in peripheral artery disease (PAD) and chronic limb-threatening ischemia (CLTI).

Teleflex (NYSE: TFX) has announced its latest quarterly dividend declaration. The company's Board of Directors has approved a cash dividend of $0.34 per share of common stock. The dividend will be distributed on March 17, 2025, to shareholders who are on record as of the close of business on March 7, 2025.

Teleflex (NYSE: TFX) reported Q4 2024 revenues of $795.4 million, up 2.8% year-over-year, with adjusted diluted EPS of $3.89 compared to $3.38 in the prior year. Full-year 2024 adjusted revenue reached $3,061.1 million, up 2.9% from the previous year.

The company recorded a significant non-cash goodwill impairment charge of $240 million in the Interventional Urology unit, primarily due to subdued UroLift revenue growth expectations. For 2025 guidance, Teleflex projects adjusted constant currency revenue growth of 1.0% to 2.0% and adjusted diluted EPS of $13.95 to $14.35.

Two major strategic announcements were made: the planned acquisition of BIOTRONIK's Vascular Intervention business and the intention to separate Teleflex into two publicly traded companies. Additionally, the company plans to initiate a $300 million accelerated share repurchase program.